If you didn't find what you were looking for, try a new search!
Hybrid Immunity Humoral and cellular responses to SARS-CoV-2 vaccination in pediatric acute lymphoblastic leukemia patients Tania Watts, University of Toronto This study aims to characterize immunity to SARS-CoV-2 in pediatric acute lymphoblastic leukemia [...]
A paper published in NPJ Vaccines by CITF-funded researcher Dr. Michael Grant (Memorial University of Newfoundland) shows that, in a group of individuals who had been infected with SARS-CoV-2, the immune response induced by the subsequent rounds of vaccination was stronger when the COVID-19 symptoms were more severe.
As the COVID-19 pandemic evolves and new variants of SARS-CoV-2 emerge, incidents of breakthrough infections among vaccinated individuals and reinfections among previously infected individuals have risen worldwide.
As of April 26, 2022, more than 3.7 million SARS-CoV-2 infections and approximately 38,847 COVID-19-related deaths have been reported in Canada. The National Advisory Committee on Immunization (NACI) recommends COVID-19 vaccinations for all Canadians over the age of 5, including those who have been previously infected.
A CITF-funded study in preprint, not yet peer-reviewed, led by Drs. Dawn Bowdish and Andrew Costa from McMaster University, showed that among residents of long-term care facilities, there was a lower risk of an Omicron infection when the person had:
A CITF-funded study, published in preprint, and not yet peer-reviewed, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV.
In a study partially funded by the CITF and published in Cell Reports, Drs. Andrés Finzi (Université de Montréal) and Renée Bazin (Héma-Québec) showed that a third vaccine dose elicited strong antibody responses regardless of the interval between the first and second doses.
A CITF-funded study published in The Lancet Gastroenterology & Hepatology by Drs. Gilaad Kaplan (University of Calgary) and Sasha Bernatsky (McGill University) on behalf of the STOP COVID-19 in IBD Research Group, showed a robust antibody response was achieved in individuals with IBD after the fourth dose of COVID-19 vaccine, similar in magnitude to that which followed the third dose.
People who are at a higher risk of severe COVID-19 include individuals with poor immune function due to underlying medical conditions or due to immune-suppressant medications. In these populations, risk mitigation measures against COVID-19 are particularly important.
According to Canadian Blood Services data published in Viruses, infection-related seroprevalence increased with the emergence of the Omicron SARS-CoV-2 variant from September 2021 to June 2022.